Synchron IPO

Synchron develops minimally invasive brain-computer interface technology that enables paralyzed patients to control digital devices through thought alone. The company's Stentrode device is inserted through blood vessels rather than requiring open brain surgery, making it significantly less risky than competing approaches. Synchron became the first company to receive FDA approval for a permanent brain-computer interface implant in humans and has successfully demonstrated patients' ability to control computers, smartphones, and other devices directly through neural signals. The company's less invasive approach and regulatory progress have positioned it as a leader in the emerging brain-computer interface market, which holds promise for treating paralysis, depression, and other neurological conditions. Synchron's technology represents a critical step toward mainstream adoption of neural interfaces for medical applications.